• Explore /
  • Poster
  • / TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Neeraj Agarwal

Neeraj Agarwal

University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Neeraj Agarwal , Neal D. Shore , Curtis Dunshee , Lawrence Ivan Karsh , Beth Sullivan , Nicola Di Santo , Mohamed Elmeliegy , Xun Lin , Ruben G.W. Quek , Akos Gabor Czibere , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03395197

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS5092)

DOI

10.1200/JCO.2019.37.15_suppl.TPS5092

Abstract #

TPS5092

Poster Bd #

201a

Abstract Disclosures

Similar Posters

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal

First Author: Elena Castro